Derek Archila
Stock Analyst at Wells Fargo
(3.89)
# 667
Out of 5,005 analysts
185
Total ratings
52.1%
Success rate
9.61%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Maintains: Overweight | $5 → $10 | $2.27 | +340.53% | 6 | Sep 23, 2025 | |
| ATYR aTyr Pharma | Downgrades: Equal-Weight | $25 → $1 | $0.78 | +29.00% | 3 | Sep 16, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $44 → $38 | $26.41 | +43.88% | 4 | Aug 20, 2025 | |
| SLNO Soleno Therapeutics | Initiates: Overweight | $123 | $59.21 | +107.74% | 1 | Aug 20, 2025 | |
| STRO Sutro Biopharma | Maintains: Equal-Weight | $4 → $3 | $0.91 | +230.21% | 1 | Aug 12, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $3 → $2 | $2.44 | -18.03% | 11 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $289 → $295 | $204.05 | +44.57% | 14 | Aug 8, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Equal-Weight | $6 → $5 | $1.61 | +210.56% | 5 | Aug 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $27 → $26 | $21.65 | +20.09% | 2 | Aug 7, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $19 → $16 | $9.61 | +66.49% | 7 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $67 → $89 | $86.85 | +2.48% | 9 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $741 → $756 | $800.00 | -5.50% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.02 | +322.89% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $129 | $99.02 | +30.28% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $53 | $57.90 | -8.46% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $26 → $29 | $23.80 | +21.85% | 12 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $18 | $20.68 | -12.96% | 4 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $25 | $9.38 | +166.52% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $7.74 | +29.20% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $2.07 | +624.64% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $36 | $40.09 | -10.20% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $30.94 | +64.84% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $16.94 | -17.36% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $3.92 | +129.59% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $16.90 | +166.27% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $5.52 | +334.78% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $3.60 | +205.56% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.19 | +213.48% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $3.30 | +506.06% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.53 | +175.65% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.08 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $37.62 | +413.02% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $72.89 | -43.75% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $18.84 | +749.26% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $12.90 | +365.12% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $5.43 | +434.07% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.32 | +3,687.88% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $17.40 | +193.10% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $22.51 | +290.94% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $24.84 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $20.01 | - | 2 | Aug 3, 2017 |
C4 Therapeutics
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.27
Upside: +340.53%
aTyr Pharma
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.78
Upside: +29.00%
Celldex Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $26.41
Upside: +43.88%
Soleno Therapeutics
Aug 20, 2025
Initiates: Overweight
Price Target: $123
Current: $59.21
Upside: +107.74%
Sutro Biopharma
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $0.91
Upside: +230.21%
Cabaletta Bio
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.44
Upside: -18.03%
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $204.05
Upside: +44.57%
Zentalis Pharmaceuticals
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.61
Upside: +210.56%
Viridian Therapeutics
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $21.65
Upside: +20.09%
Arvinas
Aug 7, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $9.61
Upside: +66.49%
Aug 6, 2025
Upgrades: Overweight
Price Target: $67 → $89
Current: $86.85
Upside: +2.48%
Jul 31, 2025
Maintains: Overweight
Price Target: $741 → $756
Current: $800.00
Upside: -5.50%
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $4.02
Upside: +322.89%
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $99.02
Upside: +30.28%
Jun 26, 2025
Maintains: Overweight
Price Target: $57 → $53
Current: $57.90
Upside: -8.46%
Jun 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $23.80
Upside: +21.85%
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $20.68
Upside: -12.96%
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $9.38
Upside: +166.52%
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $7.74
Upside: +29.20%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $2.07
Upside: +624.64%
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $40.09
Upside: -10.20%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $30.94
Upside: +64.84%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $16.94
Upside: -17.36%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $3.92
Upside: +129.59%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $16.90
Upside: +166.27%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $5.52
Upside: +334.78%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $3.60
Upside: +205.56%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $3.19
Upside: +213.48%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $3.30
Upside: +506.06%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $6.53
Upside: +175.65%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $4.08
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $37.62
Upside: +413.02%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $72.89
Upside: -43.75%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $18.84
Upside: +749.26%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $12.90
Upside: +365.12%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $5.43
Upside: +434.07%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.32
Upside: +3,687.88%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $17.40
Upside: +193.10%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $22.51
Upside: +290.94%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $24.84
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $20.01
Upside: -